Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 169, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2021.103532
Keywords
Protein degradation; PROTAC; SNIPER; Targeted therapy; Cancer
Categories
Ask authors/readers for more resources
In the era of precision medicine, targeted protein degraders are emerging biological agents that can overcome treatment resistance and druggability limitations of certain key oncogenic proteins by promoting their specific degradation.
In the era of precision medicine, monoclonal antibodies and small molecule inhibitors are the mainstays of the biological therapy in patients with solid tumors. However, resistance to treatment and the undruggability of certain key oncogenic proteins emerged as major limitations and jeopardize the clinical benefit of modern therapeutic approaches. Targeted protein degraders are novel molecules entering the early phase of clinical development that exploit the intracellular ubiquitine-proteasome system to promote a specific degradation of target proteins. Since the peculiar mechanism of action, targeted protein degraders have the potential to limit and overcome resistance to treatment and to allow a full actionability of certain cancer drivers that are actually elusive targets. Here, we discuss the state-of-the-art and the open issues in the development of these emerging biological agents from a clinical perspective and with a focus on solid tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available